Phaseline

Companies › Joint & Vascular Institute

Joint & Vascular Institute: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lipiodol
transient liquid embolic agent for lateral plantar artery embolization
–Phase 1Plantar Fasciitis, Chronic; OsteoarthritisMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07395128LipiodolPhase 1Plantar Fasciitis, ChronicOtherMar 2027
NCT06611007LipiodolPhase 1OsteoarthritisImmunologyJul 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.